Effects of olanzapine on 31P MRS metabolic markers in schizophrenia.

Abstract

Antipsychotic drug action might include mechanisms related to normalising phospholipid and high-energy metabolism. We applied brain metabolic imaging with (31)P magnetic resonance spectroscopy ((31)P MRS) and two-dimensional chemical shift imaging to assess changes of metabolism of phospholipids and high-energy phosphates in schizophrenia patients at baseline (four antipsychotic-naïve and three off antipsychotics) and at follow-up, after 6 weeks of treatment with olanzapine. Results indicate a significant increase of adenosine-triphosphate (ATP) in the right inferior temporal cortex and a trend towards ATP decrease in the left cerebellum. This suggests a shift in high-energy phosphates (rather than phospholipids), possibly related to normalisation of functioning in these areas.

• Authors: Igor Nenadic, Maren Dietzek, Kerstin Langbein, Reinhard Rzanny, Alexander Gussew, Jürgen R Reichenbach, Heinrich Sauer, Stefan Smesny
• Journal: Human psychopharmacology (Hum Psychopharmacol) Vol. 28 Issue 1 Pg. 91-3 (Jan 2013) ISSN: 1099-1077 [Electronic] England
• PMID: 23225665 (Publication Type: Journal Article)
• Copyright: Copyright © 2012 John Wiley & Sons, Ltd.

Chemical References

• Antipsychotic Agents
• Biomarkers
• Phosphorus Isotopes
• Benzodiazepines
• Olanzapine

Topics

• Adult
• Antipsychotic Agents (therapeutic use)
• Benzodiazepines (therapeutic use)
• Biomarkers (metabolism)
• Energy Metabolism (drug effects, physiology)
• Female
• Follow-Up Studies
• Humans
• Magnetic Resonance Spectroscopy (methods)
• Male
• Middle Aged
• Olanzapine
• Phosphorus Isotopes
• Pilot Projects
• Schizophrenia (diagnosis, drug therapy, metabolism)
• Treatment Outcome